411 related articles for article (PubMed ID: 32312682)
1. Emerging Mechanisms by which EMT Programs Control Stemness.
Wilson MM; Weinberg RA; Lees JA; Guen VJ
Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
3. EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling.
Guen VJ; Chavarria TE; Kröger C; Ye X; Weinberg RA; Lees JA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10532-E10539. PubMed ID: 29158396
[TBL] [Abstract][Full Text] [Related]
4. SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition?
Lourenço AR; Coffer PJ
Trends Cancer; 2017 Aug; 3(8):571-582. PubMed ID: 28780934
[TBL] [Abstract][Full Text] [Related]
5. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
Nachiyappan A; Gupta N; Taneja R
FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
[TBL] [Abstract][Full Text] [Related]
6. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
7. Noncoding RNAs in Cancer Cell Plasticity.
Xu J; Liu S
Adv Exp Med Biol; 2016; 927():173-89. PubMed ID: 27376735
[TBL] [Abstract][Full Text] [Related]
8. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
Mitra A; Mishra L; Li S
Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
[TBL] [Abstract][Full Text] [Related]
9. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
10. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
11. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells (CSCs) in cancer progression and therapy.
Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
[TBL] [Abstract][Full Text] [Related]
13. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
14. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links.
Liu X; Fan D
Curr Pharm Des; 2015; 21(10):1279-91. PubMed ID: 25506898
[TBL] [Abstract][Full Text] [Related]
15. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
Garg M
Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
[TBL] [Abstract][Full Text] [Related]
16. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
17. Landscape perspectives of tumor, EMT, and development.
Yu C; Liu Q; Chen C; Yu J; Wang J
Phys Biol; 2019 Jul; 16(5):051003. PubMed ID: 31067516
[TBL] [Abstract][Full Text] [Related]
18. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
20. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
